Credit: Imperial College London / Timothy Rawson et al. Lancet Digital Health 2019
Small, non-invasive patches worn on the skin can accurately detect the levels of medication in a patient’s system, matching the accuracy of current clinical methods.
In a small-scale clinical evaluation, researchers at Imperial College London have shown for the first time how microneedle biosensors can be used to monitor the changing concentration of antibiotics.
Their findings, published today in The Lancet Digital Health, show the sensors enable real-time monitoring of changes in antibiotic concentration in the body, with similar results to those obtained from blood tests.
The team believes the technology could change how patients with serious infections are treated by showing how quickly their bodies ‘use up’ medications they are given. The researchers add that if future development and testing proves successful and the technology reaches the clinic, it could help to cut costs for the NHS, reduce drug-resistant infections and improve treatment for patients with life-threatening infections and improve the management of less serious ones.
They add that biosensors could reduce the need for blood sampling and analysis as well as offer more efficient, personalised drug delivery that could potentially be delivered outside of the hospital setting for outpatients.
Dr Timothy Rawson, from Imperial’s Department of Infectious Disease and who led the research, said: “Microneedle biosensors hold a great potential for monitoring and treating the sickest of patients. When patients in hospital are treated for severe bacterial infections the only way we have of seeing whether antibiotics we give them are working is to wait and see how they respond, and to take frequent blood samples to analyse levels of the drugs in their system – but this can take time.
“Our biosensors could help to change that. By using a simple patch on the skin of the arm, or potentially at the site of infection, it could tell us how much of a drug is being used by the body and provide us with vital medical information, in real time.”
Microneedle biosensors use a series of microscopic ‘teeth’ to penetrate the skin and detect changes in the fluid between cells. These teeth act as electrodes to detect changes in pH and can be coated with enzymes which react with a drug of choice, altering the local pH of the surrounding tissue if the drug is present.
The technology has been used for continuous monitoring of blood sugar, but the Imperial group has, for the first time, shown its potential for use in monitoring changes to drug concentrations.
In a small proof-of-concept trial, the Imperial team trialled the sensors in 10 healthy patients who were given doses of penicillin. Sensor patches (1.5 cm sq) were placed on their forearms and connected to monitors, with measurements taken frequently – from 30 minutes before receiving oral penicillin, to four hours afterwards. Blood samples were taken at the same time points for comparison.
Data collected from nine patients revealed that the sensors could accurately detect the changing concentration of penicillin in patients’ bodies. The researchers found that while penicillin concentrations varied widely from patient to patient, the overall readings from the biosensors were similar to those from blood samples – showing a marked decrease in drug concentration over time.
According to the team, the early findings are positive, but they explain the study is limited by the very small sample size and the was only tested on a single antibiotic, in healthy patients.
The researchers explain that along with further testing in larger patient groups to strengthen the initial findings, they will look to see how the sensors could help to optimise the dosing of penicillin and similar antibiotics. They add that the sensors could form the basis of a ‘closed loop system’, like an insulin pump – where antibiotics are administered to patients and levels continuously monitored to ensure they receive a sufficient dose.
Professor Tony Cass, from the Department of Chemistry said: “This small, early-stage trial has shown that the sensor technology is as effective as gold standard clinical analysis in detecting changes to the concentrations of penicillin in the human body. When further developed, this technology could prove critical for the monitoring and treatment of patients with severe infections. More widely it could be used to monitor many other drugs and personalise treatment in many diseases”
The technology was developed through research supported by funding from the National Institute for Health Research (NIHR) and Fondation Merieux. Volunteers were recruited and treated at the NIHR Imperial Biomedical Research Centre at Imperial College Healthcare NHS Trust. This collaborative work will be advanced further through Imperial’s National Centre for Antimicrobial Research and Optimisation (CAMO)
Professor Alison Holmes, from Imperial’s Department of Infectious Disease and director of the NIHR Health Protection Research Unit in HCAI and AMR at Imperial and the CAMO, said: “This technology is an example of the close collaboration between scientists, medics and engineers going on in institutions across the UK, which could change the way we treat patients. Antibiotic resistance and drug-resistant infections are among the biggest threats to human health in the world today.”
Professor Holmes added: “Technological solutions such as our microneedle biosensor could prove crucial in improving how we use and protect the arsenal of life-saving antibiotics we have available to treat patients. Ultimately, these types of collaborative, multidisciplinary solutions could lead to earlier detection and better treatment of infections, helping to save more lives and protect these invaluable medicines for generations to come.”
The research was funded by the NIHR Imperial Biomedical Research Centre and Fondation Mérieux and supported by the infrastructure of the NIHR Health Protection Research Unit in HCAI and AMR at Imperial and the NIHR Clinical Research Facility at Imperial.
Notes to editors:
For media enquiries contact:
Research Media Officer (Medicine),
Imperial College London,
Tel: +44 (0)20 7594 2410
Email: [email protected]
1. ‘Microneedle biosensors for real-time, minimally invasive drug monitoring of penicillin: A first-in-human evaluation in healthy volunteers’ by Timothy M Rawson et al. is published in The Lancet Digital Health.
2. Imperial College London is one of the world’s leading universities. The College’s 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.
Founded in 1907, Imperial builds on a distinguished past – having pioneered penicillin, holography and fibre optics – to shape the future. Imperial researchers work across disciplines to improve health and wellbeing, understand the natural world, engineer novel solutions and lead the data revolution. This blend of academic excellence and its real-world application feeds into Imperial’s exceptional learning environment, where students participate in research to push the limits of their degrees.
Imperial is the UK’s most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK’s most innovative university because of its exceptional entrepreneurial culture and ties to industry.
3. The National Institute for Health Research (NIHR) is the nation’s largest funder of health and care research. The NIHR:
* Funds, supports and delivers high quality research that benefits the NHS, public health and social care
* Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
* Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
* Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
* Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.